Press releases
- Ligand to Acquire APEIRON Biologics AG for $100 Million
- Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
- Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
- Ligand to Participate in Upcoming Investor Conferences
- Ligand Reports First Quarter 2024 Financial Results
- Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
More ▼
Key statistics
As of last trade Ligand Pharmaceuticals Inc (LGND:DEU) traded at 93.00, 0.00% below its 52-week high of 93.00, set on Jul 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 91.50 |
---|---|
High | 93.00 |
Low | 91.00 |
Bid | 92.50 |
Offer | 94.00 |
Previous close | 92.00 |
Average volume | 50.33 |
---|---|
Shares outstanding | 17.96m |
Free float | 17.54m |
P/E (TTM) | 19.31 |
Market cap | 1.82bn USD |
EPS (TTM) | 5.23 USD |
Data delayed at least 15 minutes, as of Jul 22 2024.
More ▼